Al in Pathology Market by Neural Network (GAN, CNN, RNN), Function (Diagnostic, Image Analysis, CDSS, Data Management, Analytics), Use Case (Drug Discovery, Clinical Workflow), End User (Hospitals, Labs, Pharma/Biotech), & Region - Global Forecast to 2030

1 INTRODUCTION 28 1.1 STUDY OBJECTIVES 28 1.2 MARKET DEFINITION 28 1.3 STUDY SCOPE 29 1.3.1 MARKET SEGMENTATION AND GEOGRAPHIC SPREAD 29 1.3.2 INCLUSIONS & EXCLUSIONS 30 1.4 YEARS CONSIDERED 31 1.5 CURRENCY CONSIDERED 31 1.6 KEY STAKEHOLDERS 32 2 RESEARCH METHODOLOGY 33 2.1 RESEARCH DATA 33 2.1.1 SECONDARY DATA 34 2.1.1.1 Key data from secondary sources 35 2.1.2 PRIMARY DATA 35 2.1.2.1 Revenue share analysis illustration 37 2.2 MARKET SIZE ESTIMATION 38 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 44 2.4 RESEARCH ASSUMPTIONS 45 2.5 RESEARCH LIMITATIONS 45 2.5.1 METHODOLOGY-RELATED LIMITATIONS 45 2.5.2 SCOPE-RELATED LIMITATIONS 45 2.6 RISK ASSESSMENT 46 3 EXECUTIVE SUMMARY 47 4 PREMIUM INSIGHTS 51 4.1 KEY OPPORTUNITIES FOR PLAYERS IN AI IN PATHOLOGY MARKET 51 4.2 AI IN PATHOLOGY MARKET: REGIONAL MIX 52 4.3 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER AND KEY COUNTRY/REGION 53 4.4 GEOGRAPHIC GROWTH OPPORTUNITIES 54 5 MARKET OVERVIEW 55 5.1 INTRODUCTION 55 5.2 MARKET DYNAMICS 55 5.2.1 DRIVERS 56 5.2.1.1 Development of CNNs and advanced AI models 56 5.2.1.2 Integration of AI into multiplex imaging 56 5.2.1.3 Increasing cases of misdiagnoses in patients 57 5.2.1.4 Benefits of AI-augmented telepathology 57 5.2.1.5 Advancements in deep learning & image processing 58 5.2.2 RESTRAINTS 58 5.2.2.1 High cost of digital pathology systems 58 5.2.2.2 Limited AI expertise and varied regulatory guidelines for medical software 59 5.2.2.3 Inadequate interoperability issues with legacy systems 59 5.2.3 OPPORTUNITIES 60 5.2.3.1 Increasing demand for personalized medicines 60 5.2.3.2 Integration of multi-omics data 60 5.2.3.3 Predictive analytics for disease progression 61 5.2.4 CHALLENGES 61 5.2.4.1 Insufficient data for AI algorithms 61 5.2.4.2 Data privacy and ethical concerns 61 5.2.4.3 Challenges associated with interpretability of AI models 62 5.3 TRENDS & DISRUPTIONS IMPACTING CUSTOMER BUSINESS 63 5.4 INDUSTRY TRENDS 63 5.4.1 EVOLUTION OF AI IN PATHOLOGY 63 5.5 ECOSYSTEM ANALYSIS 64 5.6 VALUE CHAIN ANALYSIS 67 5.7 TECHNOLOGY ANALYSIS 68 5.7.1 KEY TECHNOLOGIES 68 5.7.1.1 Machine learning (ML) and artificial intelligence (AI) 68 5.7.1.2 Computer vision 68 5.7.2 COMPLEMENTARY TECHNOLOGIES 69 5.7.2.1 Cloud computing 69 5.7.3 ADJACENT TECHNOLOGIES 69 5.7.3.1 Telepathology 69 5.8 REGULATORY LANDSCAPE 70 5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70 5.8.2 REGULATIONS, BY REGION 70 5.8.2.1 North America 70 5.8.2.1.1 US 70 5.8.2.1.2 Canada 71 5.8.2.2 Europe 72 5.8.2.3 Asia Pacific 73 5.8.2.3.1 Japan 73 5.8.2.3.2 China 74 5.9 PRICING ANALYSIS 75 5.9.1 AVERAGE SELLING PRICE TREND, BY REGION 75 5.9.2 INDICATIVE PRICING ANALYSIS, BY OFFERING 75 5.10 PORTER’S FIVE FORCES ANALYSIS 76 5.10.1 THREAT FROM NEW ENTRANTS 77 5.10.2 THREAT FROM SUBSTITUTES 77 5.10.3 BARGAINING POWER OF SUPPLIERS 77 5.10.4 BARGAINING POWER OF BUYERS 77 5.10.5 INTENSITY OF COMPETITIVE RIVALRY 78 5.11 PATENT ANALYSIS 78 5.11.1 PATENT PUBLICATION TRENDS FOR AI IN PATHOLOGY SOLUTIONS 78 5.11.2 JURISDICTION AND TOP APPLICANT ANALYSIS 79 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 82 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 82 5.12.2 BUYING CRITERIA 83 5.13 END USER ANALYSIS 83 5.13.1 UNMET NEEDS OF END USERS 83 5.13.2 END USER EXPECTATIONS 84 5.14 KEY CONFERENCES AND EVENTS, 2025–2026 85 5.15 CASE STUDY ANALYSIS 86 5.15.1 CASE STUDY 1: PATBAL EMPLOYED PYTORCH FOR ITS HIGH-LEVEL PYTHONIC SYNTAX TO SUPPORT DIVERSE MODELING APPROACHES 86 5.15.2 CASE STUDY 2: KFBIO DEVELOPED KFBIO AI CERVICAL CANCER SCREENING SYSTEM TO STRENGTHEN CANCER DIAGNOSIS 86 5.15.3 CASE STUDY 3: RESEARCH TEAM FROM UNIVERSITY OF HELSINKI USED AIFORIA CREATE TO DEVELOP DEEP-LEARNING AI MODEL TO PREDICT PATIENT OUTCOMES 87 5.16 INVESTMENT & FUNDING SCENARIO 87 5.17 BUSINESS MODELS 88 5.18 IMPACT OF AI/GEN AI ON AI IN PATHOLOGY MARKET 88 5.18.1 KEY USE CASES 89 5.18.2 AI/GENERATIVE AI IMPLEMENTATION: CASE STUDY 90 5.18.2.1 Accelerated biomarker discovery and clinical trial optimization 90 5.18.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 91 5.18.3.1 Drug discovery & development market 91 5.18.3.2 Medical imaging & diagnostics market 91 5.18.4 USER READINESS AND IMPACT ASSESSMENT 92 5.18.4.1 User readiness 92 5.18.4.1.1 Pharmaceutical companies 92 5.18.4.1.2 Biopharmaceutical companies 92 5.18.4.2 Impact assessment 92 5.18.4.2.1 User A: Pharmaceutical companies 92 5.18.4.2.1.1 Implementation 92 5.18.4.2.1.2 Impact 93 5.18.4.2.2 User B: Biopharmaceutical companies 93 5.18.4.2.2.1 Implementation 93 5.18.4.2.2.2 Impact 93 5.19 TRADE ANALYSIS 93 5.19.1 IMPORT SCENARIO 94 5.19.2 EXPORT SCENARIO 95 5.20 US 2025 TARIFF 96 5.20.1 INTRODUCTION 96 5.20.2 KEY TARIFF RATES 97 5.20.3 PRICE IMPACT ANALYSIS 98 5.20.4 IMPACT ON COUNTRY/REGION 98 5.20.4.1 US 98 5.20.4.2 Europe 99 5.20.4.3 Asia Pacific 100 5.20.5 IMPACT ON END USE INDUSTRIES 100 6 AI IN PATHOLOGY MARKET, BY OFFERING 101 6.1 INTRODUCTION 102 6.2 END-TO-END SOLUTIONS 102 6.2.1 INCREASING DEMAND FOR INTEGRATED WORKFLOWS IN HEALTHCARE MODELS TO DRIVE MARKET 102 6.3 NICHE POINT SOLUTIONS 103 6.3.1 GROWING FOCUS ON PRECISION MEDICINE AND TARGETED THERAPY RESEARCH TO PROPEL MARKET 103 6.4 TECHNOLOGY 104 6.4.1 RISING NEED FOR ADVANCED DATA MANAGEMENT SOLUTIONS TO FUEL MARKET 104 6.5 HARDWARE 105 6.5.1 HIGH ADOPTION OF AI-BASED MICROSCOPES TO PROPEL MARKET 105 6.6 MICROSCOPES 107 6.6.1 NEED FOR AUTOMATED ANALYSIS OF TISSUE SAMPLES TO FUEL GROWTH 107 6.7 SCANNERS 108 6.7.1 IMPROVEMENTS IN IMAGE QUALITY AND PRECISION DIAGNOSTICS TO BOOST DEMAND 108 6.8 STORAGE SYSTEMS 110 6.8.1 NEED FOR STRUCTURED MODELS OF HIGH-RESOLUTION IMAGES TO SUPPORT MARKET GROWTH 110 7 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK 112 7.1 INTRODUCTION 113 7.2 CONVOLUTIONAL NEURAL NETWORKS (CNNS) 113 7.2.1 FOCUS ON PROVIDING HIGH-QUALITY IMAGE RECOGNITION AND OBJECTION DETECTION TO PROPEL MARKET 113 7.3 GENERATIVE ADVERSARIAL NETWORKS (GANS) 115 7.3.1 NEED FOR GENERATING ACCURATE SYNTHETIC PATHOLOGY IMAGES TO DRIVE MARKET 115 7.4 RECURRENT NEURAL NETWORKS (RNNS) 116 7.4.1 NEED FOR ANALYSIS OF SEQUENTIAL DATA AND TIME-DEPENDENT PATTERNS TO FUEL MARKET 116 7.5 OTHER NEURAL NETWORKS 118 8 AI IN PATHOLOGY MARKET, BY FUNCTION 119 8.1 INTRODUCTION 120 8.2 IMAGE ANALYSIS 121 8.2.1 DETECTION OF CELLULAR ANOMALIES AND DISEASE MARKERS TO FUEL UPTAKE 121 8.3 DIAGNOSTICS 122 8.3.1 RAPID PROCESSION OF AUTOMATED SAMPLES TO DRIVE MARKET 122 8.4 WORKFLOW MANAGEMENT 123 8.4.1 OPTIMIZATION OF LAB RESOURCES FOR HIGH-THROUGHPUT RESULTS TO FUEL UPTAKE 123 8.5 DATA MANAGEMENT 124 8.5.1 EMPHASIS ON ADVANCEMENTS IN DATA INTEGRATION AND PROCESSING TO BOOST DEMAND 124 8.6 PREDICTIVE ANALYTICS 125 8.6.1 GROWING FOCUS ON EARLY DIAGNOSIS OF DISEASES TO DRIVE MARKET 125 8.7 CDSS 126 8.7.1 PROVISION OF REAL-TIME INSIGHTS TO FUEL MARKET 126 8.8 AUTOMATED REPORT GENERATION 127 8.8.1 INCREASING DEMAND FOR QUALITY CONTROL TO DRIVE MARKET 127 8.9 QUALITY ASSURANCE TOOLS 128 8.9.1 RISING REGULATORY NEED TO ACCELERATE DEMAND FOR QUALITY ASSURANCE TOOLS TO BOOST GROWTH 128 9 AI IN PATHOLOGY MARKET, BY USE CASE 129 9.1 INTRODUCTION 130 9.2 DRUG DISCOVERY 130 9.2.1 TARGET IDENTIFICATION & SELECTION 133 9.2.1.1 Analysis of molecular and histological data for biomarker discovery to fuel market 133 9.2.2 TARGET VALIDATION 134 9.2.2.1 Increasing demand for precision medicines to drive market 134 9.2.3 HIT IDENTIFICATION & PRIORITIZATION 135 9.2.3.1 Growing requirement for rapid analysis and cost efficiency to fuel uptake 135 9.2.4 HIT-TO-LEAD IDENTIFICATION 136 9.2.4.1 Advancements in ML to support market growth 136 9.2.5 LEAD OPTIMIZATION 137 9.2.5.1 Growing focus on therapeutic efficacy to propel market 137 9.2.6 CANDIDATE SELECTION & VALIDATION 138 9.2.6.1 Critical requirement for regulatory approvals to drive market 138 9.3 DISEASE DIAGNOSIS & PROGNOSIS 139 9.3.1 INCREASING INCIDENCE OF CHRONIC DISEASES TO FUEL MARKET 139 9.4 CLINICAL WORKFLOW 140 9.4.1 STRUCTURED AUTOMATION OF EXTENSIVE VOLUME DATA TO DRIVE MARKET 140 9.5 TRAINING & EDUCATION 141 9.5.1 UTILIZATION OF DIGITAL PATHOLOGY SYSTEMS IN ACADEMIC INSTITUTES TO SUPPORT MARKET GROWTH 141 10 AI IN PATHOLOGY MARKET, BY END USER 143 10.1 INTRODUCTION 144 10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 144 10.2.1 GROWING FOCUS ON TOXICOLOGY TESTING TO PROPEL MARKET 144 10.3 HOSPITALS & REFERENCE LABORATORIES 145 10.3.1 INCREASING NEED FOR EFFECTIVE DIAGNOSES OF INFECTIOUS DISEASES TO DRIVE GROWTH 145 10.4 ACADEMIC & RESEARCH INSTITUTES 147 10.4.1 GROWING INVESTMENTS IN LIFE SCIENCES RESEARCH TO SUPPORT DEMAND 147 11 AI IN PATHOLOGY MARKET, BY REGION 148 11.1 INTRODUCTION 149 11.2 NORTH AMERICA 149 11.2.1 MACROECONOMIC OUTLOOK 149 11.2.2 US 153 11.2.2.1 High healthcare expenditure and improvements in cloud computing platforms to propel market 153 11.2.3 CANADA 157 11.2.3.1 Increasing adoption of deep learning for advanced healthcare diagnostics to drive market 157 11.3 EUROPE 160 11.3.1 MACROECONOMIC OUTLOOK 160 11.3.2 UK 163 11.3.2.1 Increased focus on drug discovery and development to boost demand 163 11.3.3 GERMANY 166 11.3.3.1 Availability of funding for AI initiatives to fuel uptake 166 11.3.4 FRANCE 169 11.3.4.1 Increasing adoption of big data in healthcare computing to fuel uptake 169 11.3.5 ITALY 172 11.3.5.1 Digital transformation and innovation in healthcare to support market growth 172 11.3.6 SPAIN 175 11.3.6.1 Increased workforce shortage to fuel market 175 11.3.7 REST OF EUROPE 178 11.4 ASIA PACIFIC 181 11.4.1 MACROECONOMIC OUTLOOK 181 11.4.2 CHINA 185 11.4.2.1 Rising cases of infectious and chronic diseases to fuel demand 185 11.4.3 JAPAN 188 11.4.3.1 Advanced healthcare infrastructure to propel market 188 11.4.4 INDIA 191 11.4.4.1 Growing focus on healthcare digitization to boost demand 191 11.4.5 REST OF ASIA PACIFIC 195 11.5 LATIN AMERICA 198 11.5.1 MACROECONOMIC OUTLOOK 198 11.5.2 BRAZIL 201 11.5.2.1 Strategic investments for AI adoption to support market growth 201 11.5.3 MEXICO 204 11.5.3.1 Growth in pharmaceutical R&D to drive market 204 11.5.4 REST OF LATIN AMERICA 207 11.6 MIDDLE EAST & AFRICA 210 11.6.1 MACROECONOMIC OUTLOOK 210 11.6.2 GCC COUNTRIES 213 11.6.2.1 Increasing investments for expansion of technological expertise to support growth 213 11.6.3 REST OF MIDDLE EAST & AFRICA 216 12 COMPETITIVE LANDSCAPE 220 12.1 INTRODUCTION 220 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 220 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN PATHOLOGY MARKET 221 12.3 REVENUE ANALYSIS, 2020−2024 223 12.4 MARKET SHARE ANALYSIS, 2024 223 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 226 12.5.1 STARS 226 12.5.2 EMERGING LEADERS 226 12.5.3 PERVASIVE PLAYERS 226 12.5.4 PARTICIPANTS 226 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 228 12.5.5.1 Company footprint 228 12.5.5.2 Offering footprint 229 12.5.5.3 Use case footprint 230 12.5.5.4 End user footprint 231 12.5.5.5 Region footprint 232   12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 233 12.6.1 PROGRESSIVE COMPANIES 233 12.6.2 RESPONSIVE COMPANIES 233 12.6.3 DYNAMIC COMPANIES 233 12.6.4 STARTING BLOCKS 233 12.6.5 COMPETITIVE BENCHMARKING 235 12.7 COMPANY VALUATION & FINANCIAL METRICS 236 12.7.1 FINANCIAL METRICS 236 12.7.2 COMPANY VALUATION 236 12.8 BRAND/PRODUCT COMPARISON 237 12.9 COMPETITIVE SCENARIO 237 12.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 237 12.9.2 DEALS 239 12.9.3 OTHER DEVELOPMENTS 241 13 COMPANY PROFILES 242 13.1 KEY PLAYERS 242 13.1.1 KONINKLIJKE PHILIPS N.V. 242 13.1.1.1 Business overview 242 13.1.1.2 Products/Services offered 243 13.1.1.3 Recent developments 244 13.1.1.3.1 Deals 244 13.1.1.4 MnM view 244 13.1.1.4.1 Key strengths 244 13.1.1.4.2 Strategic choices 244 13.1.1.4.3 Weaknesses & competitive threats 244 13.1.2 F. HOFFMANN-LA ROCHE LTD. 245 13.1.2.1 Business overview 245 13.1.2.2 Products/Services offered 246 13.1.2.3 Recent developments 247 13.1.2.3.1 Product/Service launches & approvals 247 13.1.2.3.2 Deals 248 13.1.2.4 MnM view 248 13.1.2.4.1 Key strengths 248 13.1.2.4.2 Strategic choices 248 13.1.2.4.3 Weaknesses & competitive threats 248 13.1.3 HOLOGIC, INC. 249 13.1.3.1 Business overview 249 13.1.3.2 Products/Services offered 250 13.1.3.3 Recent developments 251 13.1.3.3.1 Product/Service launches & approvals 251 13.1.3.4 MnM view 251 13.1.3.4.1 Key strengths 251 13.1.3.4.2 Strategic choices 251 13.1.3.4.3 Weaknesses & competitive threats 251 13.1.4 AKOYA BIOSCIENCES, INC. 252 13.1.4.1 Business overview 252 13.1.4.2 Products/Services offered 253 13.1.4.3 Recent developments 254 13.1.4.3.1 Deals 254 13.1.4.4 MnM view 255 13.1.4.4.1 Key strengths 255 13.1.4.4.2 Strategic choices 255 13.1.4.4.3 Weaknesses & competitive threats 255 13.1.5 AIFORIA TECHNOLOGIES PLC 256 13.1.5.1 Business overview 256 13.1.5.2 Products/Services offered 257 13.1.5.3 Recent developments 258 13.1.5.3.1 Deals 258 13.1.5.4 MnM view 260 13.1.5.4.1 Key strengths 260 13.1.5.4.2 Strategic choices 260 13.1.5.4.3 Weaknesses & competitive threats 260 13.1.6 INDICA LABS INC. 261 13.1.6.1 Business overview 261 13.1.6.2 Products/Services offered 261 13.1.6.3 Recent developments 262 13.1.6.3.1 Product/Service launches & approvals 262 13.1.6.3.2 Deals 263 13.1.6.3.3 Expansions 265 13.1.7 OPTRASCAN 266 13.1.7.1 Business overview 266 13.1.7.2 Products/Services offered 266 13.1.7.3 Recent developments 267 13.1.7.3.1 Other developments 267 13.1.8 IBEX MEDICAL ANALYTICS LTD. 268 13.1.8.1 Business overview 268 13.1.8.2 Products/Services offered 268 13.1.8.3 Recent developments 269 13.1.8.3.1 Product/Service launches & approvals 269 13.1.8.3.2 Deals 270   13.1.9 MINDPEAK GMBH 272 13.1.9.1 Business overview 272 13.1.9.2 Products/Services offered 272 13.1.9.3 Recent developments 273 13.1.9.3.1 Product/Service launches & approvals 273 13.1.9.3.2 Deals 273 13.1.9.3.3 Other developments 274 13.1.10 TRIBUN HEALTH 275 13.1.10.1 Business overview 275 13.1.10.2 Products/Services offered 275 13.1.10.3 Recent developments 276 13.1.10.3.1 Deals 276 13.1.11 TECHCYTE, INC. 277 13.1.11.1 Business overview 277 13.1.11.2 Products/Services offered 277 13.1.11.3 Recent developments 278 13.1.11.3.1 Product/Service launches & approvals 278 13.1.11.3.2 Deals 278 13.1.11.3.3 Other developments 279 13.1.12 DEEP BIO INC. 280 13.1.12.1 Business overview 280 13.1.12.2 Products/Services offered 280 13.1.12.3 Recent developments 281 13.1.12.3.1 Deals 281 13.1.13 LUMEA INC. 282 13.1.13.1 Business overview 282 13.1.13.2 Products/Services offered 282 13.1.13.3 Recent developments 283 13.1.13.3.1 Deals 283 13.1.14 VISIOPHARM 284 13.1.14.1 Business overview 284 13.1.14.2 Products/Services offered 284 13.1.14.3 Recent developments 285 13.1.14.3.1 Product/Service launches & approvals 285 13.1.14.3.2 Expansions 285 13.1.15 AETHERAI 287 13.1.15.1 Business overview 287 13.1.15.2 Products/Services offered 287 13.1.15.3 Recent developments 288 13.1.15.3.1 Deals 288   13.1.16 AIOSYN 289 13.1.16.1 Business overview 289 13.1.16.2 Products/Services offered 289 13.1.16.3 Recent developments 290 13.1.16.3.1 Product/Service launches & approvals 290 13.1.16.3.2 Deals 291 13.1.16.3.3 Other developments 291 13.1.17 PAIGE AI, INC. 292 13.1.17.1 Business overview 292 13.1.17.2 Products/Services offered 292 13.1.17.3 Recent developments 293 13.1.17.3.1 Product/Service launches & approvals 293 13.1.17.3.2 Deals 295 13.1.17.3.3 Other developments 295 13.1.18 PROSCIA, INC. 296 13.1.18.1 Business overview 296 13.1.18.2 Products/Services offered 296 13.1.18.3 Recent developments 297 13.1.18.3.1 Product/Service launches & approvals 297 13.1.18.3.2 Deals 298 13.1.18.3.3 Other developments 298 13.1.19 PATHAI, INC. 299 13.1.19.1 Business overview 299 13.1.19.2 Products/Services offered 299 13.1.19.3 Recent developments 300 13.1.19.3.1 Product/Service launches & approvals 300 13.1.19.3.2 Deals 301 13.1.20 TEMPUS LABS, INC. 303 13.1.20.1 Business overview 303 13.1.20.2 Products/Services offered 304 13.1.20.3 Recent developments 304 13.1.20.3.1 Product/Service launches & approvals 304 13.2 OTHER PLAYERS 305 13.2.1 KONFOONG BIOINFORMATION TECH CO., LTD. 305 13.2.2 DOMORE DIAGNOSTICS AS 306 13.2.3 QRITIVE 306 13.2.4 DEEPATHOLOGY LTD 307 13.2.5 4D PATH INC. 308   14 APPENDIX 309 14.1 DISCUSSION GUIDE 309 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 316 14.3 CUSTOMIZATION OPTIONS 318 14.4 RELATED REPORTS 318 14.5 AUTHOR DETAILS 319

TABLE 1 EXCHANGE RATES, 2021–2024 31 TABLE 2 ROLE OF PLAYERS IN MARKET ECOSYSTEM 66 TABLE 3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70 TABLE 4 US FDA: MEDICAL DEVICE CLASSIFICATION 71 TABLE 5 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 71 TABLE 6 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 72 TABLE 7 EUROPE: CLASSIFICATION OF IVD DEVICES 72 TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 74 TABLE 9 CHINA: CLASSIFICATION OF MEDICAL DEVICES 74 TABLE 10 INDICATIVE PRICING ANALYSIS, BY OFFERING 75 TABLE 11 IMPACT OF PORTER’S FORCES 77 TABLE 12 JURISDICTION ANALYSIS OF TOP APPLICANTS IN AI IN PATHOLOGY MARKET 79 TABLE 13 KEY PATENTS IN AI IN PATHOLOGY MARKET 81 TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 82 TABLE 15 KEY BUYING CRITERIA, BY END USER 83 TABLE 16 UNMET NEEDS OF END USERS 84 TABLE 17 AI IN PATHOLOGY MARKET: END USER EXPECTATIONS 84 TABLE 18 LIST OF CONFERENCES AND EVENTS, 2025–2026 85 TABLE 19 IMPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2023 (USD THOUSAND) 95 TABLE 20 EXPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2023 (USD MILLION) 96 TABLE 21 RECIPROCAL TARIFF RATES ADJUSTED BY US 97 TABLE 22 TARIFF RATES FOR AI IN PATHOLOGY PRODUCTS 97 TABLE 23 EXPECTED CHANGE IN PRICES AND THEIR IMPACT ON END USER PRODUCTS DUE TO TARIFF IMPACT 98 TABLE 24 AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 102 TABLE 25 AI IN PATHOLOGY MARKET FOR END-TO-END SOLUTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 103 TABLE 26 AI IN PATHOLOGY MARKET FOR NICHE POINT SOLUTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 104 TABLE 27 AI IN PATHOLOGY MARKET FOR TECHNOLOGY, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 105 TABLE 28 AI IN PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2023–2030 (USD MILLION) 106 TABLE 29 AI IN PATHOLOGY MARKET FOR HARDWARE, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 106 TABLE 30 AI IN PATHOLOGY MARKET FOR MICROSCOPES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 108 TABLE 31 AI IN PATHOLOGY MARKET FOR SCANNERS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 109 TABLE 32 AI IN PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 111 TABLE 33 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 113 TABLE 34 AI IN PATHOLOGY MARKET FOR CONVOLUTIONAL NEURAL NETWORKS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 114 TABLE 35 AI IN PATHOLOGY MARKET FOR GENERATIVE ADVERSARIAL NETWORKS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 116 TABLE 36 AI IN PATHOLOGY MARKET FOR RECURRENT NEURAL NETWORKS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 117 TABLE 37 AI IN PATHOLOGY MARKET FOR OTHER NEURAL NETWORKS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 118 TABLE 38 AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 120 TABLE 39 AI IN PATHOLOGY MARKET FOR IMAGE ANALYSIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 121 TABLE 40 AI IN PATHOLOGY MARKET FOR DIAGNOSTICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 122 TABLE 41 AI IN PATHOLOGY MARKET FOR WORKFLOW MANAGEMENT, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 123 TABLE 42 AI IN PATHOLOGY MARKET FOR DATA MANAGEMENT, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 124 TABLE 43 AI IN PATHOLOGY MARKET FOR PREDICTIVE ANALYTICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 125 TABLE 44 AI IN PATHOLOGY MARKET FOR CDSS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 126 TABLE 45 AI IN PATHOLOGY MARKET FOR AUTOMATED REPORT GENERATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 127 TABLE 46 AI IN PATHOLOGY MARKET FOR QUALITY ASSURANCE TOOLS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 128 TABLE 47 AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 130 TABLE 48 DRUG DISCOVERY APPLICATIONS FOR AI IN PATHOLOGY 131 TABLE 49 AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2023–2030 (USD MILLION) 131 TABLE 50 AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 132 TABLE 51 AI IN PATHOLOGY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 133 TABLE 52 AI IN PATHOLOGY MARKET FOR TARGET VALIDATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 134 TABLE 53 AI IN PATHOLOGY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 135 TABLE 54 AI IN PATHOLOGY MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 136 TABLE 55 AI IN PATHOLOGY MARKET FOR LEAD OPTIMIZATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 137 TABLE 56 AI IN PATHOLOGY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 138 TABLE 57 AI IN PATHOLOGY MARKET FOR DISEASE DIAGNOSIS & PROGNOSIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 140 TABLE 58 AI IN PATHOLOGY MARKET FOR CLINICAL WORKFLOW, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 141 TABLE 59 AI IN PATHOLOGY MARKET FOR TRAINING & EDUCATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 142 TABLE 60 AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 144 TABLE 61 AI IN PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 145 TABLE 62 AI IN PATHOLOGY MARKET FOR HOSPITALS & REFERENCE LABORATORIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 146 TABLE 63 AI IN PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 147 TABLE 64 AI IN PATHOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION) 149 TABLE 65 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 66 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 151 TABLE 67 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 152 TABLE 68 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 152 TABLE 69 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 153 TABLE 70 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 153 TABLE 71 US: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 155 TABLE 72 US: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 155 TABLE 73 US: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 156 TABLE 74 US: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 156 TABLE 75 US: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 157 TABLE 76 CANADA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 158 TABLE 77 CANADA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 158 TABLE 78 CANADA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 159 TABLE 79 CANADA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 159 TABLE 80 CANADA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 160 TABLE 81 EUROPE: AI IN PATHOLOGY MARKET, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 161 TABLE 82 EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 161 TABLE 83 EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 162 TABLE 84 EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 162 TABLE 85 EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 163 TABLE 86 EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 163 TABLE 87 UK: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 164 TABLE 88 UK: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 165 TABLE 89 UK: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 165 TABLE 90 UK: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 166 TABLE 91 UK: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 166 TABLE 92 GERMANY: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 167 TABLE 93 GERMANY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 167 TABLE 94 GERMANY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 168 TABLE 95 GERMANY: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 168 TABLE 96 GERMANY: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 169 TABLE 97 FRANCE: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 170 TABLE 98 FRANCE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 170 TABLE 99 FRANCE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 171 TABLE 100 FRANCE: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 171 TABLE 101 FRANCE: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 172 TABLE 102 ITALY: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 173 TABLE 103 ITALY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 173 TABLE 104 ITALY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 174 TABLE 105 ITALY: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 174 TABLE 106 ITALY: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 175 TABLE 107 SPAIN: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 176 TABLE 108 SPAIN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 176 TABLE 109 SPAIN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 177 TABLE 110 SPAIN: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 177 TABLE 111 SPAIN: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 178 TABLE 112 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 179 TABLE 113 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 179 TABLE 114 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 180 TABLE 115 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 180 TABLE 116 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 181 TABLE 117 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 183 TABLE 118 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 183 TABLE 119 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 184 TABLE 120 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 184 TABLE 121 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 185 TABLE 122 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 185 TABLE 123 CHINA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 186 TABLE 124 CHINA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 186 TABLE 125 CHINA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 187 TABLE 126 CHINA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 187 TABLE 127 CHINA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 188 TABLE 128 JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 189 TABLE 129 JAPAN: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 189 TABLE 130 JAPAN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 190 TABLE 131 JAPAN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 190 TABLE 132 JAPAN: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 191 TABLE 133 JAPAN: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 191 TABLE 134 INDIA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 192 TABLE 135 INDIA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 193 TABLE 136 INDIA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 193 TABLE 137 INDIA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 194 TABLE 138 INDIA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 194 TABLE 139 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 195 TABLE 140 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 196 TABLE 141 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 196 TABLE 142 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 197 TABLE 143 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 197 TABLE 144 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 199 TABLE 145 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 199 TABLE 146 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 200 TABLE 147 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 200 TABLE 148 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 201 TABLE 149 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 201 TABLE 150 BRAZIL: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 202 TABLE 151 BRAZIL: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 202 TABLE 152 BRAZIL: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 203 TABLE 153 BRAZIL: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 203 TABLE 154 BRAZIL: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 204 TABLE 155 MEXICO: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 205 TABLE 156 MEXICO: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 205 TABLE 157 MEXICO: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 206 TABLE 158 MEXICO: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 206 TABLE 159 MEXICO: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 207 TABLE 160 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 208 TABLE 161 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 208 TABLE 162 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 209 TABLE 163 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 209 TABLE 164 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 210 TABLE 165 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION) 211 TABLE 166 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 211 TABLE 167 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 212 TABLE 168 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 212 TABLE 169 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 213 TABLE 170 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 213 TABLE 171 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 214 TABLE 172 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 215 TABLE 173 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 215 TABLE 174 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 216 TABLE 175 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 216 TABLE 176 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 217 TABLE 177 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 217 TABLE 178 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 218 TABLE 179 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 218 TABLE 180 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 219 TABLE 181 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES 221 TABLE 182 AI IN PATHOLOGY MARKET: DEGREE OF COMPETITION 224 TABLE 183 OFFERING FOOTPRINT 229 TABLE 184 USE CASE FOOTPRINT 230 TABLE 185 END USER FOOTPRINT 231 TABLE 186 REGION FOOTPRINT 232 TABLE 187 AI IN PATHOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SMES 235 TABLE 188 AI IN PATHOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 235 TABLE 189 AI IN PATHOLOGY MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025 237 TABLE 190 AI IN PATHOLOGY MARKET: DEALS, JANUARY 2021–APRIL 2025 239 TABLE 191 AI IN PATHOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2021– APRIL 2025 241 TABLE 192 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 242 TABLE 193 KONINKLIJKE PHILIPS N.V.: PRODUCTS/SERVICES OFFERED 243 TABLE 194 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021–APRIL 2025 244 TABLE 195 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 245 TABLE 196 F. HOFFMANN LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED 246 TABLE 197 F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021−MARCH 2025 247 TABLE 198 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021−MARCH 2025 248 TABLE 199 HOLOGIC, INC.: COMPANY OVERVIEW 249 TABLE 200 HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED 250 TABLE 201 HOLOGIC, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021−APRIL 2025 251 TABLE 202 AKOYA BIOSCIENCES, INC.: COMPANY OVERVIEW 252 TABLE 203 AKOYA BIOSCIENCES, INC.: PRODUCT/SERVICES OFFERED 253 TABLE 204 AKOYA BIOSCIENCES, INC.: DEALS, JANUARY 2021−APRIL 2025 254 TABLE 205 AIFORIA TECHNOLOGIES PLC: COMPANY OVERVIEW 256 TABLE 206 AIFORIA TECHNOLOGIES PLC: PRODUCT/SERVICES OFFERED 257 TABLE 207 AIFORIA TECHNOLOGIES PLC: DEALS, JANUARY 2021−APRIL 2025 258 TABLE 208 INDICA LABS INC.: COMPANY OVERVIEW 261 TABLE 209 INDICA LABS INC.: PRODUCTS/SERVICES OFFERED 261 TABLE 210 INDICA LABS INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021−APRIL 2025 262 TABLE 211 INDICA LABS INC.: DEALS, JANUARY 2021−APRIL 2025 263 TABLE 212 INDICA LABS INC.: EXPANSIONS, JANUARY 2021–APRIL 2025 265 TABLE 213 OPTRASCAN: COMPANY OVERVIEW 266 TABLE 214 OPTRASCAN: PRODUCTS/SERVICES OFFERED 266 TABLE 215 OPTRASCAN: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025 267 TABLE 216 IBEX MEDICAL ANALYTICS LTD.: COMPANY OVERVIEW 268 TABLE 217 IBEX MEDICAL ANALYTICS LTD.: PRODUCTS/SERVICES OFFERED 268 TABLE 218 IBEX MEDICAL ANALYTICS LTD.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025 269 TABLE 219 IBEX MEDICAL ANALYTICS LTD: DEALS, JANUARY 2021–APRIL 2025 270 TABLE 220 MINDPEAK GMBH: COMPANY OVERVIEW 272 TABLE 221 MINDPEAK GMBH: PRODUCTS/SERVICES OFFERED 272 TABLE 222 MINDPEAK GMBH: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025 273 TABLE 223 MINDPEAK GMBH: DEALS, JANUARY 2021–APRIL 2025 273 TABLE 224 MINDPEAK GMBH: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025 274 TABLE 225 TRIBUN HEALTH: COMPANY OVERVIEW 275 TABLE 226 TRIBUN HEALTH: PRODUCTS/SERVICES OFFERED 275 TABLE 227 TRIBUN HEALTH: DEALS, JANUARY 2021–APRIL 2025 276 TABLE 228 TECHCYTE, INC.: COMPANY OVERVIEW 277 TABLE 229 TECHCYTE, INC.: PRODUCTS/SERVICES OFFERED 277 TABLE 230 TECHCYTE, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025 278 TABLE 231 TECHCYTE, INC.: DEALS, JANUARY 2021–APRIL 2025 278 TABLE 232 TECHCYTE, INC.: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025 279 TABLE 233 DEEP BIO INC.: COMPANY OVERVIEW 280 TABLE 234 DEEP BIO INC.: PRODUCTS/SERVICES OFFERED 280 TABLE 235 DEEP BIO INC.: DEALS, JANUARY 2021–APRIL 2025 281 TABLE 236 LUMEA INC.: COMPANY OVERVIEW 282 TABLE 237 LUMEA INC.: PRODUCTS/SERVICES OFFERED 282 TABLE 238 LUMEA INC.: DEALS, JANUARY 2021–APRIL 2025 283 TABLE 239 VISIOPHARM: COMPANY OVERVIEW 284 TABLE 240 VISIOPHARM: PRODUCTS/SERVICES OFFERED 284 TABLE 241 VISIOPHARM: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025 285 TABLE 242 VISIOPHARM: EXPANSIONS, JANUARY 2021– APRIL 2025 285 TABLE 243 AETHERAI: COMPANY OVERVIEW 287 TABLE 244 AETHERAI: PRODUCTS/SERVICES OFFERED 287 TABLE 245 AETHERAI: DEALS, JANUARY 2021– APRIL 2025 288 TABLE 246 AIOSYN: COMPANY OVERVIEW 289 TABLE 247 AIOSYN: PRODUCTS/SERVICES OFFERED 289 TABLE 248 AIOSYN: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025 290 TABLE 249 AIOSYN: DEALS, JANUARY 2021–APRIL 2025 291 TABLE 250 AIOSYN: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025 291 TABLE 251 PAIGE AI, INC.: COMPANY OVERVIEW 292 TABLE 252 PAIGE AI, INC.: PRODUCTS/SERVICES OFFERED 292 TABLE 253 PAIGE AI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021– APRIL 2025 293 TABLE 254 PAIGE AI, INC.: DEALS, JANUARY 2021–APRIL 2025 295 TABLE 255 PAIGE AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025 295 TABLE 256 PROSCIA, INC.: COMPANY OVERVIEW 296 TABLE 257 PROSCIA, INC.: PRODUCTS/SERVICES OFFERED 296 TABLE 258 PROSCIA, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025 297 TABLE 259 PROSCIA, INC.: DEALS, JANUARY 2021–APRIL 2025 298 TABLE 260 PROSCIA, INC.: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025 298 TABLE 261 PATHAI, INC.: COMPANY OVERVIEW 299 TABLE 262 PATHAI, INC.: PRODUCTS/SERVICES OFFERED 299 TABLE 263 PATHAI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025 300 TABLE 264 PATHAI, INC.: DEALS, JANUARY 2021–APRIL 2025 301 TABLE 265 TEMPUS LABS, INC.: COMPANY OVERVIEW 303 TABLE 266 TEMPUS LABS, INC.: PRODUCTS/SERVICES OFFERED 304 TABLE 267 TEMPUS LABS, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025 304 TABLE 268 KONFOONG BIOINFORMATION TECH CO., LTD.: COMPANY OVERVIEW 305 TABLE 269 DOMORE DIAGNOSTICS AS: COMPANY OVERVIEW 306 TABLE 270 QRITIVE: COMPANY OVERVIEW 306 TABLE 271 DEEPPATH: COMPANY OVERVIEW 307 TABLE 272 4D PATH INC.: COMPANY OVERVIEW 308 FIGURE 1 RESEARCH DESIGN 33 FIGURE 2 KEY PRIMARY SOURCES 36 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 37 FIGURE 4 MARKET SIZE ESTIMATION PROCESS 38 FIGURE 5 KEY INSIGHTS FROM INDUSTRY EXPERTS 39 FIGURE 6 BOTTOM-UP APPROACH: END USER SPENDING ON AI IN PATHOLOGY 40 FIGURE 7 AI IN PATHOLOGY MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2025–2030) 41 FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 42 FIGURE 9 TOP-DOWN APPROACH 43 FIGURE 10 DATA TRIANGULATION METHODOLOGY 44 FIGURE 11 AI IN PATHOLOGY MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION) 47 FIGURE 12 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2025 VS. 2030 (USD MILLION) 48 FIGURE 13 AI IN PATHOLOGY MARKET, BY USE CASE, 2025 VS. 2030 (USD MILLION) 48 FIGURE 14 AI IN PATHOLOGY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 49 FIGURE 15 AI IN PATHOLOGY MARKET: GEOGRAPHIC SNAPSHOT 50 FIGURE 16 DEVELOPMENT OF CONVOLUTIONAL NEURAL NETWORKS (CNNS) AND AI LEARNING MODELS TO PROPEL MARKET 51 FIGURE 17 NORTH AMERICA TO LEAD MARKET DURING FORECAST PERIOD 52 FIGURE 18 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT AND CHINA ACCOUNTED FOR SIGNIFICANT SHARE IN 2024 53 FIGURE 19 INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 54 FIGURE 20 AI IN PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 55 FIGURE 21 HEALTHCARE BREACHES REPORTED TO US DEPARTMENT OF HEALTH AND HUMAN SERVICES (SEPTEMBER 2024) 62 FIGURE 22 TRENDS & DISRUPTIONS IMPACTING CUSTOMER BUSINESS 63 FIGURE 23 ECOSYSTEM ANALYSIS 65 FIGURE 24 VALUE CHAIN ANALYSIS 67 FIGURE 25 EUROPE: IVDR TIMELINE 73 FIGURE 26 PORTER’S FIVE FORCES 76 FIGURE 27 NUMBER OF PATENTS PUBLISHED, JANUARY 2017−APRIL 2025 78 FIGURE 28 NUMBER OF PATENT DOCUMENTS, BY JURISDICTION 79 FIGURE 29 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS), JANUARY 2017–APRIL 2025 80 FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 82 FIGURE 31 KEY BUYING CRITERIA, BY END USER 83 FIGURE 32 FUNDING ACTIVITIES IN AI IN PATHOLOGY MARKET 87 FIGURE 33 MARKET POTENTIAL OF AI/GENERATIVE AI IN PATHOLOGY 89 FIGURE 34 IMPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2023 (USD) 94 FIGURE 35 EXPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2023 (USD THOUSAND) 95 FIGURE 36 NORTH AMERICA: AI IN PATHOLOGY MARKET SNAPSHOT 150 FIGURE 37 ASIA PACIFIC: AI IN PATHOLOGY MARKET SNAPSHOT 182 FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS, 2020−2024 (USD MILLION) 223 FIGURE 39 AI IN PATHOLOGY MARKET: MARKET SHARE ANALYSIS (2024) 224 FIGURE 40 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 227 FIGURE 41 AI IN PATHOLOGY MARKET: COMPANY FOOTPRINT 228 FIGURE 42 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 234 FIGURE 43 EV/EBITDA OF KEY VENDORS 236 FIGURE 44 YTD PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF AI IN PATHOLOGY VENDORS 236 FIGURE 45 BRAND/PRODUCT COMPARISON 237 FIGURE 46 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2024) 243 FIGURE 47 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024) 246 FIGURE 48 HOLOGIC, INC.: COMPANY SNAPSHOT (2024) 250 FIGURE 49 AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2023) 253 FIGURE 50 AIFORIA TECHNOLOGIES PLC: COMPANY SNAPSHOT (2024) 256 FIGURE 51 TEMPUS: COMPANY SNAPSHOT (2024) 303